5Blade J, SamsonD, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. european group for blood and marrow transplant. Br J Haematol, 1998,102 : 1115-1123.
6Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 2003, 78:21-33.
7Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol, 1994, 12:2398-2404.
8Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol, 1991,47:262-267.
9Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111: 2516 -2520.
10Pineda-Roman M, Zangari M, Hssler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol, 2008, 140: 625- 634.
